South Korea has quietly but decisively positioned itself as one of the world’s leading destinations for clinical research. For Australian professionals working across regulatory affairs, clinical operations and pharmacovigilance, understanding the Korean landscape is no longer optional. It is increasingly strategic.

With a population of approximately 52 million, South Korea combines scale with density. Unlike Australia’s dispersed geography, the Korean population is concentrated in major metropolitan hubs, particularly Seoul. This concentration supports rapid patient recruitment, efficient site management and streamlined logistics. Life expectancy is high, healthcare infrastructure is technologically advanced, and the vast majority of citizens are covered by national health insurance. The result is a sophisticated, well-resourced environment that is highly conducive to clinical research.

South Korea consistently ranks among the top five countries globally for clinical trial activity. More than 200 medical institutions are designated to conduct clinical trials, and over 26 dedicated Phase I units operate across the country, offering more than 700 research beds. Most sites operate with electronic medical records and electronic IRB systems, further enhancing operational efficiency. Importantly, all registered study staff, including investigators, pharmacists and coordinators, must complete Korean Good Clinical Practice training, reinforcing a strong compliance culture.

From a therapeutic perspective, Korea presents interesting epidemiological contrasts with Australia. Higher rates of lung, liver and stomach cancers coexist with rising Western-style chronic diseases such as diabetes and cardiovascular disease. For sponsors designing global development programs, these demographic and disease patterns can be highly attractive.

Regulatory Pathways: Structured and Predictable

Clinical trial initiation in South Korea requires both regulatory authority approval from the Ministry of Food and Drug Safety and Institutional Review Board approval. The initial IND review typically takes around 12 weeks, with the regulator issuing comments within approximately 30 working days. Sponsors should anticipate a full start-up timeline of roughly five to six months, factoring in document preparation, translation and contract negotiations.

A notable operational consideration is translation. Core documents such as the protocol, informed consent form and certain chemistry, manufacturing and controls elements require Korean language submission. While some documents may be submitted in English, patient-facing materials must be translated. In practice, translation can add four to six weeks to preparation timelines.

Import permits are mandatory for investigational product, laboratory kits and certain equipment, and investigational product labelling must include Korean language elements. Contracting processes typically require signature by the institutional chairperson, with the principal investigator co-signing. These governance nuances differ from Australian practice and warrant early planning.

Safety Reporting: Structured and Digitised

Korea’s safety reporting framework is robust and clearly differentiated by product type. For post-marketing drugs, serious adverse drug reactions must be reported within 15 days. In clinical trials, serious unexpected suspected adverse reactions that are fatal or life-threatening require reporting within seven days, with other such reactions reported within 15 days.

Electronic reporting is conducted via the E2B R3 gateway for medicinal products. Korea has implemented ICH E2B R3 requirements since 2021, requiring specific Korean extensions within electronic case safety reports. Companies must incorporate country-specific fields, including Korean causality assessment terminology, before submission to the authority.

Development Safety Update Reports must follow ICH guidance, with key sections translated into Korean and entered into the regulatory system. While sponsors may request adverse event datasets from the authority for product renewal purposes, there is currently no open access searchable public database.

Strategic Opportunity for Australian Sponsors

For Australian organisations seeking to diversify trial footprints or accelerate recruitment, South Korea offers a compelling proposition. Dense patient populations, technologically advanced hospitals, disciplined regulatory processes and a mature pharmacovigilance infrastructure combine to create a highly attractive environment.

However, success requires an appreciation of local regulatory expectations, translation requirements, labelling standards and reporting extensions. The Korean system is not simply a mirror of Australia’s regulatory framework. It is structured, precise and increasingly harmonised with global ICH standards, but retains distinct national features.

As global development programs continue to expand across the Asia Pacific region, South Korea stands out as a strategic partner. For ARCS members navigating multinational development pathways, understanding this powerhouse jurisdiction is both timely and essential.